Concepedia
Statistics
Publications
53
Citations
3.3K
H-Index
32
Active since
1992
Affiliations
Pfizer (United States)(Current)
Pearl River Community College
Memorial Sloan Kettering Cancer Center
National Cancer Institute
Cornell University
Frank Loganzo is an author at Pfizer (United States) specializing in pharmacology, medicine, and oncology.
Publications per year
1992–2022
Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
Frank Loganzo, Xingzhi Tan, Matthew Sung et al. · Molecular Cancer Therapeutics · 2015 · 270 citations
Medicine, Immunology, Oncology +17
Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.
J A Reed, Frank Loganzo, C R Shea et al. · PubMed · 1995 · 262 citations
Life Sciences, Genetics, Molecular Genetics +17
Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)
Matthew Sung, Xingzhi Tan, Bingwen Lu et al. · Molecular Cancer Therapeutics · 2017 · 208 citations
Medicine, Oncology, Pharmacology +17
Mild Method for Succinimide Hydrolysis on ADCs: Impact on ADC Potency, Stability, Exposure, and Efficacy
L. Nathan Tumey, Manoj B. Charati, Tao He et al. · Bioconjugate Chemistry · 2014 · 189 citations
Pharmacy, Pharmaceutics, Pharmacokinetics +12
Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of β-tubulin (Asp26Glu) and less stable microtubules
Malathi Hari, Frank Loganzo, Tami Annable et al. · Molecular Cancer Therapeutics · 2006 · 147 citations
1–5 of 53